Assertio Holdings, Inc.

After the speaker's remarks, there will be a question and answer session. If you would like to ask a question during this time, simply press star followed by the number one on your telephone keypad. If you would like to withdraw your question, press star one again. Thank you. I would now like to turn the call over to Matt Kreps, investor relations for the company. Please go ahead.

Thank you, Eric. Good afternoon, and thank you all for joining us today to discuss Assertio's fourth quarter and full year 2024 financials. The news release covering our results for this period is now available on the investor page of our website at investor.assertiotx.com. I would encourage you to review the release and tables in conjunction with today's discussion. With me today are Brendan O'Grady, our Chief Executive Officer, and A.J. Patel, Chief Financial Officer. In just a moment, Brendan will open the remarks and provide an overview of the business. Then AJ will cover our financial results and we'll return to discuss our guidance. After that, we will take questions from our covering research analysts. Please note that during this call, management will make projections and other forward-looking statements regarding our future performance. Such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, including those noted in this afternoon's press release, as well as the CERTIOS filings with the SEC. These and our other risks are more fully described in the risk factor section and other sections of our annual report on Form 10-K and in our Form 10-Q filings. Our actual results may differ materially from those projected in the forward-looking statements, and SRDO specifically disclaims any intent or obligation to update these forward-looking statements except as required by law. And with that, I want to turn the call over to Brendan. Please go ahead.

Thank you, Matt. I'd like to start by welcoming everyone to today's call and thanking you for joining us. I'll begin my comments with some overall perspectives on 2024 and then turn the call over to AJ to discuss Q4 and 2024 full-year financials. I'll then come back after AJ to discuss our 2025 outlook before we take questions from our covering analysts. As you know, I've been in the CEO chair for about nine months now. During that time, I've been able to assess the overall business, the growth drivers, structure, operating model, speedy landscape, and talent. I'm happy to say that over the course of my first nine months, we have addressed needs in all of those areas and are making progress to return Assertio to growth sooner rather than later. My perspective is that from late 23 to 2026 is a pivotal time in Assertio's evolution. Companies go through cycles as lead assets transition, and Assertio is no different. That is why I think of 2024 as our year of stabilization when this transition phase was new. I think of 2025 as our year of transformation as we prepare for the future. And I think of 2026 as the year that the growth phase begins and we are aligning our strategy accordingly. To explain a little more why I characterize 2024 as the stabilization year, Assyria was coming off the acquisition and integration of Spectrum and the subsequent loss of exclusivity of Indusyn. In addition to managing the loss of exclusivity of Indusyn, 2024 was focused on making the transition from Indusyn to Rolvidon as the lead asset. Part of that transition was adjusting to the reality that Rolvidon is a very different asset than Indusyn. It competes in a very different market with different economics and requires a different go-to-market approach. However, it has given us a good foundation to build from especially in oncology and oncology supportive care. So I think stabilization is the correct word to describe that journey. Overall, I am proud of what we've accomplished in 2024, not only with Rolvidon and Indicent, but across the board as we have made great strides. Specifically, we exceeded 60 million in Rolvidon sales, growing our share in the community oncology clinic segment where we have primarily focused, managed the erosion of Indicent due to generic competition, and optimize the rest of the portfolio, stabilizing the P&L in the process. We generated good cash flow and financial contributions from all our assets and now have a stronger balance sheet to deploy in our transformation efforts in 2025. We completed and presented the Rolvidon same-day dosing trial that we believe supports the use of Rolvidon as a safe and effective agent when given the same-day as chemotherapy treatment. We completed a commercial pilot project for Simpazan to confirm that growth is not only possible, but probable with the addition of in-person promotion. We also added new talent to our leadership team with the appointment of Mary Petriga as chief commercial officer and in tandem appointed former chief commercial officer and former chief financial officer Paul Schwichtenberg as chief transformation officer. Lastly, we made changes and added new talent to our board with the appointment of David Stark, a former colleague of mine and former chief legal officer of Teva Pharmaceuticals, and Mark Reisenhower, a seasoned pharmaceutical senior executive with 30 plus years of commercial experience, including significant oncology experience. And of course, Heather Mason, board member, the interim CEO prior to my arrival, also became chair of our board. As I sit here today, we are in a stronger position on all levels than we were just nine months ago to deliver on our commitment to return Assertio to growth. With that as a prelude, I will turn it over to AJ to discuss our financial performance in 2024. Thanks, Brendan.